Erythrocytic enzymes and antioxidant status in people with type 2 diabetes: Beneficial effect of Syzygium cumini leaf extract in vitro

Diabetes Research and Clinical Practice

Volumn 94, Issue 1, 2011, Pages 84-90

  De Bona, Karine Santos ^a   Bellé, Luziane Potrich ^a   Bittencourt, Paula Eliete Rodrigues ^a   Bonfanti, Gabriela ^a   Cargnelluti, Lariane Oliveira ^a   Pimentel, Victor Camera ^a   Ruviaro, Amanda Roggia ^a   Schetinger, Maria Rosa Chitolina ^a   Emanuelli, Tatiana ^a   Moretto, Maria Beatriz ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Acetylcholinesterase; Adenosine deaminase; Diabetes mellitus; Oxidative stress; Syzygium cumini

Indexed keywords

ACETYLCHOLINESTERASE; ADENOSINE DEAMINASE; ANTIOXIDANT; ASCORBIC ACID; CATALASE; ERYTHROCYTE ENZYME; SUPEROXIDE DISMUTASE; SYZYGIUM CUMINI EXTRACT; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOL GROUP;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; FEMALE; HEMOLYSATE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PLANT LEAF; VITAMIN BLOOD LEVEL;

ACETYLCHOLINESTERASE; ADENOSINE DEAMINASE; ANTIOXIDANTS; CATALASE; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; ERYTHROCYTES; EUGENIA; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PLANT EXTRACTS; PLANT LEAVES; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 80054891200     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.06.008     Document Type: Article

References (49)

1. Kim S.H., Hyun S.H., Choung S.Y. Anti-diabetic effect of cinnamon extract on blood glucose in db/db mice. J Ethnopharmacol 2006, 104:119-123.
2. Pu L.J., Lu L., Xu X.W., Zhang R.Y., Zhang Q., Zhang J.S., et al. Value of serum glycated albumin and high-sensitivity C reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2006, 5:27.
3. Lebeche D., Davidoff A.J., Hajjar R.J. Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat Clin Pract Cardiovasc Med 2008, 5:715-724.
4. Halliwell B., Gutteridge J.M.C. Oxygen free radicals and iron in relation to biology and medicine: some problems and concept. Arch Biochem Biophys 1986, 246:501-514.
5. Rohn T.T., Nelson L.K., Waeg G., Quinn M.T. U-101033E (2,4-diaminopyrolloppyrimidine), a potent inhibitor of membrane lipid peroxidation as assessed by the production of 4-hydroxynonenal malondialdehyde, and 4-hydroxynonenal-protein adducts. Biochem Pharmacol 1998, 56:1371-1379.
6. Sands W.A., Palmer T.M. Adenosine receptors and the control of endothelial cell function in inflammatory disease. Immunol Lett Rev 2005, 101:1-11.
7. Uluoglu C., Cimen B., Ozbey G., Karasu C., Durakoglugil D.B., Gunes A., et al. The effect of experimental diabetes on the circadian pattern of adenosine deaminase and myeloperoxidase activities in rat liver. Gen Physiol Biophys 2008, 27:25-31.
8. Pawelczyk T., Sakowicz M., Szczepanska-Konkel M., Angielski S. Decreased expression of adenosine kinase in streptozotocin-induced diabetes mellitus rats. Arch Biochem Biophys 2000, 375:1-6.
9. Bax B.E., Bain M.D., Fairbanks L.D., Webster A.D.B., Chalmers R.A. In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol-conjugated and native adenosine deaminase. Br J Haematol 2000, 109:549-554.
10. Bielat K., Tritsch G.L. Ecto-enzyme activity of human erythrocyte adenosine deaminase. Mol Cell Biochem 1989, 86:135-142.
11. Silman I., Sussman J.L. Acetylcholinesterase: classical and non classical functions and pharmacology. Curr Opin Pharmacol 2005, 5:293-302.
12. Mazzanti C.M., Spanevello R.M., Pereira L.B., Gonçalves J.F., Kaizer R., Corrêa M., et al. Acetylcholinesterase activity in rats experimentally demyelinated with ethidium bromide and treated with interferon beta. Neurochem Res 2006, 31:1027-1032.
13. Grover J.K., Yadav S., Vats V. Medicinal plants of India with anti diabetic potential. J Ethnopharmacol 2002, 81:81-100.
14. Sabu M.C., Kuttan R. Anti diabetic activity of medicinal plants and its relationship with their antioxidant property. J Ethnopharmacol 2002, 81:155-160.
15. Teixeira C.C., Fuchs F.D. The efficacy of herbal medicines in clinical models: the case of jambolan. J Ethnopharmacol 2006, 108:16-19.
16. Prince M.S., Kamalakkannan N., Menon V.P. Syzigium cumini seed extracts reduce tissue damage in diabetic rat brain. J Ethnopharmacol 2003, 84:205-209.
17. Villasenõr I.M., Lamadrid M.R. Comparative anti-hyperglycemic potentials of medicinal plants. J Ethnopharmacol 2006, 104:129-131.
18. Kedar P., Chakrabarti C.H. Effects of jambolan seed treatment on blood sugar, lipids and urea in streptozotocin induced diabetes in rabbits. Indian J Physiol Pharmacol 1983, 27:135-140.
19. Helmstädter A. Syzygium cumini (L.) SKEELS (Myrtaceae) against diabetes-125 years of research. Pharmazie 2008, 63:91-101.
20. Teixeira C.C., Rava C.A., Mallman da Silva P.M., Melchior R., Argenta R., Anselmi F., et al. Absence of antihyperglycemic effect of jambolan in experimental and clinical models. J Ethnopharmacol 2000, 71:343-347.
21. Bopp A., De Bona K.S., Bellé L.P., Moresco R.N., Moretto M.B. Syzygium cumini inhibits adenosine deaminase activity and reduces glucose levels in hyperglycemic patients. Fundam Clin Pharmacol 2009, 23:501-507.
22. De Bona K.S., Bellé L.P., Sari M.H., Thomé G., Schetinger M.R.C., Morsch V.M., et al. Syzygium cumini extract decrease adenosine deaminase, 5'nucleotidase activities and oxidative damage in platelets of diabetic patients. Cell Physiol Biochem 2010, 26:729-738.
23. Geiger JD, Padua AR, Nagy JI. Adenosine deaminase regulation of purine actions. In: Phillis JW, editor. Adenosine and adenine nucleotides as regulators of cellular function. Boca Raton; 1991. p. 71-84.
24. Neumann S., Razen M., Habermehl P., Meyer C.U., Zepp F., Kirkpatrick C.J., et al. The nonneuronal cholinergic system in peripheral blood cells: effects of nicotinic and muscarinic receptor antagonists on phagocytosis, respiratory burst and migration. Life Sci 2007, 80:2361-2364.
25. Eidi A., Eidi M., Esmaeili E. Antidiabetic effect of garlic (Allium sativum L.) in normal and streptozotocin-induced diabetic rats. Phytomedicine 2006, 13:624-629.
26. Marchesi V.T., Palade G.E. The localization of Mg-Na-K-activated adenosine triphosphatase on red cell ghost membranes. J Cell Biol 1967, 35:385-404.
27. Giusti G., Gakis C. Temperature conversion factors, activation energy, relative substrate specificity and optimum pH of adenosine deaminase from human serum and tissues. Enzyme 1971, 12:417-425.
28. Ellman G.L., Courtney K.D., Andres V., Feather R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961, 7:88-95.
29. Worek F., Mast U., Kiderlen D., Diepold C., Eyer P. Improved determination of acetylcholinesterase activity in human whole blood. Clin Chim Acta 1999, 288:73-90.
30. Moore R.B., Brummitt M.L., Mankad V.N. Hydroperoxides selectively inhibit human erythrocyte membrane enzymes. Arch Biochem Biophys 1989, 273:527-534.
31. Aebi H. Catalase in vitro. Methods Enzymol 1984, 105:121-127.
32. McCord J., Fridowich I. Superoxide Dismutase, an enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969, 244:6049-6055.
33. Galley H., Davies M.J., Webster N.R. Ascorbil radical formation in patients with sepsis: effects of ascorbate loading. Free Radic Biol Med 1996, 20:139-143.
34. Jacqes-Silva M.C., Nogueira C.W., Broch L.C., Flores E.M.M., Rocha J.B.T. Diphenyl disselenides and ascorbic acid changes deposition of selenium and brain of mice. Phamacol Toxicol 2001, 88:119-125.
35. Boyne A.F., Ellman G.L. A methodology for analysis of tissue sulfhydryl components. Anal Biochem 1972, 46:639-653.
36. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 1977, 83:346-356.
37. Rolo A.P., Palmeira C.M. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 2006, 212:167-178.
38. Rutkiewicz J., Górski J. On the role of insulin in regulation of adenosine deaminase activity in rat tissues. FEBS Lett 1990, 271:79-80.
39. Jackson E.K., Mi Z., Koehler M.T., Carcillo J.A., Herzer W.A. Injured erythrocytes release adenosine deaminase into the circulation. J Pharmacol Exp Ther 1996, 279:1250-1260.
40. Rao A.A., Sridhar G.R., Das U.N. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Med Hypotheses 2007, 69:1272-1276.
41. Cox D.A., Vita J.A., Treasure C.B. Atherosclerosis impairs flow mediated dilation of coronary arteries in humans. Circulation 1989, 80:458-465.
42. Koch H.P., Jager W., Groh U., Plank G. In vitro inhibition of adenosine deaminase by flavonoids and related compounds. New insight into the mechanism of action of plant phenolics. Methods Find Exp Clin Pharmacol 1992, 14:413-417.
43. Melzig M.F. Inhibition of adenosine-deaminase activity of aortic endothelial-cells by selected flavonoids. Planta Med 1996, 62:20-21.
44. Snyder L.M., Fortier N.L., Trainor J., Jacobs J., Leb L., Lubin B., et al. Effect of hydrogen peroxide exposure normal human erythrocyte deformability, morphology, surface characteristics, and spectrin-hemoglobin cross-linking. J Clin Invest 1985, 76:1971-1977.
45. Hebbel R.P., Leung A., Mohandas N. Oxidation-induced changes in microrheology properties of the red blood cell membrane. Blood 1990, 76:1015-1020.
46. Ramakrishna V., Jailkhani R. Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol 2008, 45:41-46.
47. Mãrtensson J., Han J., Griffith O.W., Meister A. Glutathione ester delays the onset of scurvy in ascorbate-deficient guinea pigs. Proc Natl Acad Sci 1993, 90:317-321.
48. Braun L., Csala M., Poussu A., Garzo T., Mandl J., Banhegyi G. Glutathione depletion induces glycogenolysis dependent ascorbate synthesis in isolated murine hepatocytes. FEBS Lett 1996, 388:173-176.
49. Howell J.G., Zibari G.B., Brown M.F., Berney D.L., Sawaya D.E., Olinde J.G., et al. Both ischemic and pharmacological preconditioning decrease hepatic leukocyte/endothelial cell interactions. Transplantation 2000, 69:300-314.